MORE►
bioinformatics
David Gascoigne, CEO of Almaden Genomics [Photo: Almaden]
Dallas’ Almaden Genomics Launches New Data Management and Informatics Service Business
by David Seeley | Sep 18, 2024
Almaden—which was formerly part of IBM Research before launching as a standalone company in 2022 under Catalyze Dallas ownership—aims to complement its g.nome workflow platform with the new service business. The goal: providing solutions that streamline data analysis and management in drug discovery, diagnostics, biotech research, and more.
by Lance Murray |
Jun 9, 2023
Ellen Gordon has worked for more than two decades on behalf of pharmaceutical and biotech companies to deliver insights and much-needed solutions. "Her experience supporting the swift development of novel medicines makes her ideal for helping our clients leverage g.nome to accelerate drug discovery," CEO David Gascogine said.
MORE►
by David Seeley |
Jan 30, 2023
Life sciences industry veteran David Gascoigne will lead the new startup, which was launched in October by Catalyze Dallas Holdings.
Almaden's g.nome cloud-native platform offers "an advanced visual drag-and-drop workflow builder" and curated library of toolkits that can speed bioinformatic pipeline building "from what previously has taken months to mere hours," the company says.
MORE►
by Lance Murray |
Nov 9, 2022
The Perot family’s support will expand the number of students admitted to UT Southwestern's dual-degree program as well as research disciplines in which they study, to include biomedical engineering, computational biology, bioinformatics, and data science.
The funding will enhance the curriculum and experiences of Medical Scientist Training Program students and increase efforts to recruit students from elite U.S. colleges, including top international students who want to stay in the U.S. for their careers.
MORE►
